Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Paul M. Ridker, M.D.


This page shows the publications co-authored by Paul Ridker and Eugene Braunwald.
Connection Strength

  1. HMG CoA reduction in patients with average cholesterol concentrations. Clin Chem. 2011 Jul; 57(7):1072-3.
    View in: PubMed
    Score: 0.466
  2. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol. 2005 May 17; 45(10):1644-8.
    View in: PubMed
    Score: 0.308
  3. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation. 2000 May 09; 101(18):2149-53.
    View in: PubMed
    Score: 0.218
  4. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1999 Jul 20; 100(3):230-5.
    View in: PubMed
    Score: 0.206
  5. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998 Sep 01; 98(9):839-44.
    View in: PubMed
    Score: 0.194
  6. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol. 2009 Mar; 29(3):424-30.
    View in: PubMed
    Score: 0.099
  7. Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy. J Thromb Thrombolysis. 2006 Aug; 22(1):71-6.
    View in: PubMed
    Score: 0.084
  8. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005 Jan 06; 352(1):20-8.
    View in: PubMed
    Score: 0.075
  9. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet. 2015 Jun 06; 385(9984):2264-2271.
    View in: PubMed
    Score: 0.038
  10. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation. 2007 Mar 27; 115(12):1528-36.
    View in: PubMed
    Score: 0.022
  11. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2005 Oct 18; 46(8):1417-24.
    View in: PubMed
    Score: 0.020
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.